Manages moderate pruritus. ANDA 212357, held by Amneal. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 212357 (Doxepin Hydrochloride), held by Amneal, was first approved by FDA on Aug 16, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Doxepin HCl cream, 5% is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus (see DOSAGE AND ADMINISTRATION ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 16, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxepin Hydrochloride5% · cream;topical | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters